Fluicell

Fluicell Net Tangible Assets

The Net Tangible Assets of Fluicell (FLUI.ST) as of Nov 20, 2026 is 10.90 M SEK. In the previous year, Net Tangible Assets was 19.08 M SEK — a change of -42.87% (lower).

Net Tangible Assets

10.90 MSEK

YoY

-42.87%

Last updated:

Net Tangible Assets of Fluicell is 2025 10.90 M SEK. Net Tangible Assets of Fluicell was 2024 19.08 M SEK. It decreases by -42.87% lower compared to the previous year.

The Fluicell Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
22.93 M SEK
Jan 1, 2019
9.83 M SEK
Jan 1, 2020
19.15 M SEK
Jan 1, 2021
18.82 M SEK
Jan 1, 2022
23.20 M SEK
Jan 1, 2023
229,000.00 SEK
Jan 1, 2024
19.08 M SEK
Jan 1, 2025
10.90 M SEK
The Fluicell Net Tangible Assets history
YEARNet Tangible AssetsYoY
10.90 MSEK-42.87%
19.08 MSEK+8,231.88%
229,000.00SEK-99.01%
23.20 MSEK+23.31%
18.82 MSEK-1.76%
19.15 MSEK+94.85%
9.83 MSEK-57.13%
22.93 MSEK+152.33%
9.09 MSEK+393.54%
1.84 MSEK+165.27%
694,000.00SEK-41.54%
1.19 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Net Tangible Assets of Fluicell is 10.90 M SEK in 2025.

Net Tangible Assets of Fluicell changed from 19.08 M SEK to 10.90 M SEK, representing a -42.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Fluicell since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fluicell

All Key Metrics — Fluicell